Access the world's leading financial data and tools

Subscribe for $2
Overview
Profile

Haisco Pharmaceutical Group Co stock

002653.SZ
CNE100001BC7

Price

33.82 CNY
Today +/-
+0.08 CNY
Today %
+1.79 %

Haisco Pharmaceutical Group Co stock price

CNY
%
Weekly
Details

Price

ⓘ

Overview

The Quote Chart provides detailed and dynamic insights into the Haisco Pharmaceutical Group Co stock's performance, showcasing daily, weekly, or monthly aggregated quotes. Users can switch between different time frames to analyze the stock's progression meticulously and make informed investment decisions.

Intraday Feature

The intraday feature provides real-time data, allowing investors to view the Haisco Pharmaceutical Group Co stock’s price fluctuations within the trading day, facilitating timely and strategic investment decisions.

Total Return and Relative Price Change

View the total return of the Haisco Pharmaceutical Group Co stock to gauge its profitability over time. The relative price change, based on the first quote available in the selected timeframe, offers insights into the stock’s performance, assisting in evaluating its investment potential.

Interpretation and Investment

Utilize the comprehensive data presented in the Quote Chart to analyze Haisco Pharmaceutical Group Co's market trends, price movements, and potential returns. Make informed investment choices by comparing different time frames and evaluating intraday data for optimized portfolio management.

Haisco Pharmaceutical Group Co Stock Price History

DateHaisco Pharmaceutical Group Co Price
12/27/202433.82 CNY
12/26/202433.22 CNY
12/25/202433.29 CNY
12/24/202433.81 CNY
12/23/202433.80 CNY
12/20/202434.60 CNY
12/19/202434.80 CNY
12/18/202434.99 CNY
12/17/202434.85 CNY
12/16/202434.99 CNY
12/13/202435.38 CNY
12/12/202435.18 CNY
12/11/202434.85 CNY
12/10/202435.30 CNY
12/9/202436.91 CNY
12/6/202436.80 CNY
12/5/202436.94 CNY
12/4/202437.45 CNY
12/3/202438.50 CNY
12/2/202438.68 CNY

Haisco Pharmaceutical Group Co Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into Haisco Pharmaceutical Group Co, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Haisco Pharmaceutical Group Co from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Haisco Pharmaceutical Group Co’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of Haisco Pharmaceutical Group Co. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into Haisco Pharmaceutical Group Co’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing Haisco Pharmaceutical Group Co’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Haisco Pharmaceutical Group Co’s growth potential.

Haisco Pharmaceutical Group Co Revenue, EBIT and net profit per share

DateHaisco Pharmaceutical Group Co RevenueHaisco Pharmaceutical Group Co EBITHaisco Pharmaceutical Group Co Net Income
2026e5.94 B CNY860.52 M CNY848.34 M CNY
2025e4.97 B CNY661.55 M CNY627.77 M CNY
2024e4.08 B CNY400.97 M CNY432.65 M CNY
20233.36 B CNY400.67 M CNY295.11 M CNY
20223.02 B CNY178.98 M CNY277 M CNY
20212.77 B CNY113.37 M CNY345.06 M CNY
20203.33 B CNY439.8 M CNY636.6 M CNY
20193.94 B CNY539.5 M CNY493.9 M CNY
20183.43 B CNY341.2 M CNY333.2 M CNY
20171.86 B CNY108.5 M CNY237.6 M CNY
20161.44 B CNY260.7 M CNY442.8 M CNY
20151.21 B CNY338 M CNY372.2 M CNY
20141.21 B CNY386.9 M CNY450.5 M CNY
2013992.3 M CNY416.6 M CNY519.2 M CNY
2012802.1 M CNY320.6 M CNY443.1 M CNY
2011604.4 M CNY280.9 M CNY312.3 M CNY
2010581.6 M CNY290.9 M CNY305.8 M CNY
2009484.6 M CNY270.7 M CNY283.7 M CNY
2008358.8 M CNY208.8 M CNY195.1 M CNY

Haisco Pharmaceutical Group Co Income Statement, Balance Sheet, Cash Flow Statement

  • Simple

  • Expanded

  • Income Statement

  • Balance Sheet

  • Cashflow

 
REVENUE (B CNY)REVENUE GROWTH (%)GROSS MARGIN (%)GROSS INCOME (B CNY)NET INCOME (M CNY)NET INCOME GROWTH (%)DIV. (CNY)DIV. GROWTH (%)SHARES (B)DOCUMENTS
20082009201020112012201320142015201620172018201920202021202220232024e2025e2026e
0.360.480.580.60.80.991.211.211.441.863.433.943.332.773.023.364.084.975.94
-35.2020.043.9632.7823.6921.980.1718.4029.3484.5914.92-15.44-16.708.7311.2821.6421.7119.55
68.7269.8364.3765.4074.4472.8869.6766.9174.0864.4956.3965.7667.9265.8569.3271.0358.3947.9840.13
0.250.340.370.40.60.720.840.811.061.21.932.592.261.832.092.38000
195283305312443519450372442237333493636345277295432627848
-45.137.772.3041.9917.16-13.29-17.3318.82-46.3840.5148.0529.01-45.75-19.716.5046.4445.1435.25
-------------------
-------------------
1.081.081.081.081.071.081.081.071.071.071.071.081.071.081.071.09000
-------------------
Details

Keystats

ⓘ

Revenue and Growth

The Haisco Pharmaceutical Group Co Revenue and Revenue Growth are pivotal to understanding the company's financial health and operational efficiency. A consistent increase in revenue indicates a company’s ability to effectively market and sell its products or services, while the revenue growth percentage offers insights into the pace at which the company is expanding over the years.

Gross Margin

The Gross Margin is a crucial metric that showcases the percentage of revenue exceeding the cost of goods sold (COGS). A higher gross margin is indicative of a company’s efficiency in controlling its production costs, thereby promising potential profitability and financial stability.

EBIT and EBIT Margin

EBIT (Earnings Before Interest and Taxes) and EBIT Margin offer deep insights into a company’s profitability, excluding the impacts of interest and taxes. Investors often assess these metrics to gauge the operational efficiency and inherent profitability of a business, separate from its financial structure and tax environment.

Income and Growth

Net Income and its subsequent growth are quintessential for investors looking to understand a company’s profitability. Consistent income growth underscores a company’s ability to enhance its profitability over time, reflecting operational efficiency, strategic competitiveness, and financial health.

Shares Outstanding

Shares outstanding refer to the total number of shares a company has issued. It's instrumental in calculating key metrics like Earnings Per Share (EPS) which is pivotal for investors to evaluate a company’s profitability on a per-share basis, offering a more granular view of financial health and valuation.

Interpreting Year to Year Comparison

Comparing yearly data allows investors to identify trends, assess the company’s growth, and anticipate potential future performance. Analyzing how metrics like revenue, income, and margins change year over year can provide valuable insights into the company’s operational efficiency, competitiveness, and overall financial health.

Expectations and Predictions

Investors often juxtapose the current and past financial data with the market’s expectations. This comparison aids in assessing whether the Haisco Pharmaceutical Group Co is performing as anticipated, underperforming or outperforming the market predictions, providing pivotal data for investment decisions.

 
ASSETSCASH BALANCE (B CNY)RECEIVABLES (M CNY)OTHER REC. (M CNY)INVENTORIES (M CNY)OTHER CURRENT LIAB. (B CNY)CURRENT ASSETS (B CNY)TANGIBLE ASSETS (B CNY)LONG-T. INVEST. (M CNY)LONG-T. REC. (M CNY)INTANGIBLE ASSETS (B CNY)GOODWILL (M CNY)OTHER NON-CURRENT ASSETS (M CNY)NON-CURRENT ASSETS (B CNY)TOTAL ASSETS (B CNY)LIABILITIESCOMMON STOCK (B CNY)ADDITIONAL PAID-IN CAPITAL (M CNY)RETAINED EARNINGS (B CNY)OTHER EQUITY (M CNY)UNREAL. GAINS/LOSSES (M CNY)EQUITY (B CNY)LIABILITIES (M CNY)PROVISIONS (M CNY)OTHER SHORT-TERM LIAB. (M CNY)SHORT-TERM DEBTS (M CNY)LONG-TERM DEBT PORTION (M CNY)SHORT-TERM REC. (B CNY)LONG-T. LIAB. (B CNY)DEFERRED TAXES (M CNY)OTHER LIAB. (M CNY)LONG-T. LIABILITIES (B CNY)DEBT (B CNY)TOTAL CAPITAL (B CNY)
2008200920102011201220132014201520162017201820192020202120222023
                               
0.080.120.380.51.291.050.861.191.181.020.620.890.820.570.771.32
58.12.502.213.718.321.627.8199.3444.3742.1533.3452.2518.49727.59799.24
57.749.714.914.628.739.831.935.267.756.536.294.7146.5146.78129.18174.39
14.939.220.72832.865.26978.8121.1146.2148.7189.3223.9259.95346281.29
0.040.020.020.050.170.421.140.050.710.140.430.370.450.050.080.07
0.250.230.430.591.531.592.121.392.281.811.982.082.11.552.052.64
0.080.10.160.20.310.450.60.680.720.80.891.091.161.171.11
0.500021.523.624.4107.7159.3452.7440.5661.7410561.3625.33483.38
000000000000019.2512.670
0.010.010.030.050.040.080.130.30.350.490.620.961.181.51.942.18
0000000000000000
11.55.310.537.542.7301.112.3759.6232.7548.8432.3251.1147.4200.44316.87350.71
0.10.120.20.290.410.860.761.841.472.32.392.962.93.463.994.01
0.350.350.630.881.952.462.873.233.744.114.375.0455.016.056.65
                               
00.010.360.360.41.081.081.081.081.081.081.081.071.081.081.11
18.510.110.112.5709.429.227.927.927.922.522.594.578.697.62100.82853.38
0.20.120.080.40.60.8211.161.331.081.111.41.791.741.822.24
00000005.215.17.715.117.1-15.59.4223.9526.64
0000000000000-42.0936.08-42.07
0.220.140.450.771.711.932.112.272.452.192.232.62.932.883.064.19
27.818.221.37.128.95749.99379.2290.6677.9615.8420301.4242.44208.99
0.310.54.32.97.211.344.450.674.4282.2322560.5323.6123.71139.87201.6
84.1164.397.467.1110.1184.3227.2249.1237456.6368.6320.1202.7306.3313.63148.09
012.10050229.7400600600804.7650650740452.94490.64104.29
206.30.60.70.500021.4200.130350.130333.78301.97841
0.130.210.120.080.20.480.720.991.012.032.052.51.721.521.491.5
0.0100.0200000.030.200.260.080.330.461.320.87
0000000.30.50.60.611.61.31.112.534.01
0.32.932.136.741.847.945.845.2284103.86780.689.4102.5498.52108.85
0.0100.050.040.040.050.050.080.490.10.320.160.430.571.430.98
0.140.210.180.120.240.530.771.071.52.142.372.662.142.092.912.48
0.350.350.630.881.952.462.883.343.954.324.65.255.074.975.976.67
Details

Balance Sheet

ⓘ

Understanding the Balance Sheet

The balance sheet of Haisco Pharmaceutical Group Co provides a detailed financial snapshot, revealing the company's assets, liabilities, and equity at a specific point in time. Analyzing these components is crucial for investors looking to understand Haisco Pharmaceutical Group Co's financial health and stability.

Assets

Haisco Pharmaceutical Group Co's assets represent everything the company owns or controls that has monetary value. These are categorized into current and non-current assets, offering insights into the company's liquidity and long-term investments.

Liabilities

Liabilities are obligations that Haisco Pharmaceutical Group Co must settle in the future. Analyzing the ratio of liabilities to assets provides insights into the company's financial leverage and risk exposure.

Equity

Equity refers to the residual interest in the assets of Haisco Pharmaceutical Group Co after deducting liabilities. It represents the owners’ claim on the company’s assets and earnings.

Year-to-Year Analysis

Comparing balance sheet figures year-to-year allows investors to identify trends, growth patterns, and potential financial risks, facilitating informed investment decisions.

Interpreting the Data

Detailed analysis of assets, liabilities, and equity can provide investors with comprehensive insights into Haisco Pharmaceutical Group Co's financial standing, aiding in investment evaluations and risk assessments.

 
NET INCOME (M CNY)DEPRECIATION (M CNY)DEFERRED TAXES (M CNY)CHANGES IN WORKING CAPITAL (M CNY)NON-CASH ITEM (M CNY)PAID INTEREST (M CNY)PAID TAXES (M CNY)NET CASH FLOW FROM OPERATING ACTIVITIES (M CNY)CAPITAL EXPENDITURES (M CNY)CASH FLOW FROM INVESTING ACTIVITIES (M CNY)CASH FLOW FROM OTHER INVESTING ACTIVITIES (M CNY)INTEREST INCOME AND EXPENSES (M CNY)NET DEBT CHANGE (M CNY)NET CHANGE IN EQUITY (M CNY)CASH FLOW FROM FINANCING ACTIVITIES (M CNY)CASH FLOW FROM OTHER FINANCING ACTIVITIES (M CNY)TOTAL DIVIDENDS PAID (M CNY)NET CHANGE IN CASH FLOW (B CNY)FREE CASH FLOW (M CNY)SHARE-BASED COMPENSATION (M CNY)
200820092010201120122013201420152016201720182019202020212022
000000000000000
000000000000000
000000000000000
-70514425-64-121-283-373-438-403-1,170-2,420-2,216-1,754-1,739
000000000000000
000000000000000
-53-102-121-156-132-185-192-194-209-286-481-497-373-173-197
943683672604645685024434093914727642063594
-37-24-80-117-125-164-234-283-208-393-352-582-601-702-700
-37-41-80-117-948-577-273-20913-229-244-514-559281-539
0-1700-822-413-38742211631076742984160
000000000000000
-6-73-2049179170232188178-6514524122857
000000000000000
-8-282-31-19545-115-109-106-136-316-44628-85-187624
0687173682-108-3915-551222011614
-1-281-122-1-240-303-281-230-286-510-325-238-130-426-247
0.270.460.70.520.720.751.11.141.350.921.913.962.362.092.23
57344.2286.5143.1339.5404.4267.7159.3200.9-1.5120.6181.6-395.5-667.14-605.62
000000000000000

Haisco Pharmaceutical Group Co stock margins

The Haisco Pharmaceutical Group Co margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Haisco Pharmaceutical Group Co. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Haisco Pharmaceutical Group Co.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the Haisco Pharmaceutical Group Co's sales revenue. A higher gross margin percentage indicates that the Haisco Pharmaceutical Group Co retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the Haisco Pharmaceutical Group Co's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the Haisco Pharmaceutical Group Co's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Haisco Pharmaceutical Group Co's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Haisco Pharmaceutical Group Co. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Haisco Pharmaceutical Group Co's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

Haisco Pharmaceutical Group Co Margin History

Haisco Pharmaceutical Group Co Gross marginHaisco Pharmaceutical Group Co Profit marginHaisco Pharmaceutical Group Co EBIT marginHaisco Pharmaceutical Group Co Profit margin
2026e71.05 %14.49 %14.29 %
2025e71.05 %13.32 %12.64 %
2024e71.05 %9.82 %10.6 %
202371.05 %11.94 %8.8 %
202269.31 %5.94 %9.19 %
202165.86 %4.09 %12.44 %
202067.93 %13.21 %19.12 %
201965.76 %13.7 %12.54 %
201856.4 %9.96 %9.72 %
201764.51 %5.85 %12.8 %
201674.11 %18.16 %30.84 %
201566.89 %27.88 %30.7 %
201469.68 %31.96 %37.21 %
201372.89 %41.98 %52.32 %
201274.5 %39.97 %55.24 %
201165.44 %46.48 %51.67 %
201064.32 %50.02 %52.58 %
200969.83 %55.86 %58.54 %
200868.56 %58.19 %54.38 %

Haisco Pharmaceutical Group Co Stock Sales Revenue, EBIT, Earnings per Share

The Haisco Pharmaceutical Group Co earnings per share therefore indicates how much revenue Haisco Pharmaceutical Group Co has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Sales per Share
EBIT per share
Earnings per Share
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Haisco Pharmaceutical Group Co earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Haisco Pharmaceutical Group Co's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Haisco Pharmaceutical Group Co’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Haisco Pharmaceutical Group Co's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Haisco Pharmaceutical Group Co Revenue, EBIT and net profit per share

DateHaisco Pharmaceutical Group Co Sales per ShareHaisco Pharmaceutical Group Co EBIT per shareHaisco Pharmaceutical Group Co Earnings per Share
2026e5.3 CNY0 CNY0.76 CNY
2025e4.44 CNY0 CNY0.56 CNY
2024e3.64 CNY0 CNY0.39 CNY
20233.07 CNY0.37 CNY0.27 CNY
20222.83 CNY0.17 CNY0.26 CNY
20212.58 CNY0.11 CNY0.32 CNY
20203.1 CNY0.41 CNY0.59 CNY
20193.63 CNY0.5 CNY0.46 CNY
20183.2 CNY0.32 CNY0.31 CNY
20171.74 CNY0.1 CNY0.22 CNY
20161.34 CNY0.24 CNY0.41 CNY
20151.13 CNY0.31 CNY0.35 CNY
20141.12 CNY0.36 CNY0.42 CNY
20130.92 CNY0.39 CNY0.48 CNY
20120.75 CNY0.3 CNY0.41 CNY
20110.56 CNY0.26 CNY0.29 CNY
20100.54 CNY0.27 CNY0.28 CNY
20090.45 CNY0.25 CNY0.26 CNY
20080.33 CNY0.19 CNY0.18 CNY

Haisco Pharmaceutical Group Co business model

Haisco Pharmaceutical Group Co is one of the most popular companies on Eulerpool.com.
LIMITED TIME OFFER

The World’s Best Investors Are On Eulerpool

Subscribe for $2

Haisco Pharmaceutical Group Co Eulerpool Fair Value

Details

Fair Value

ⓘ

Understanding Fair Value

The fair value of a stock provides insights into whether the stock is currently undervalued or overvalued. It is calculated based on profit, revenue, or dividends and offers a comprehensive perspective of the stock’s intrinsic value.

Income-Based Fair Value

This is calculated by multiplying the earnings per share by the average P/E ratio of the selected past years for smoothing. If the fair value is higher than the current market price, it suggests that the stock is undervalued.

Example 2022

Fair Value Profit 2022 = Earnings per Share 2022 / Average P/E Ratio 2019 - 2021 (3 Years Smoothing)

Revenue-Based Fair Value

It is derived by multiplying the revenue per share by the average price-to-sales ratio of the selected past years for smoothing. An undervalued stock is identified if the fair value exceeds the ongoing market price.

Example 2022

Fair Value Revenue 2022 = Revenue per Share 2022 / Average PSR 2019 - 2021 (3 Years Smoothing)

Dividend-Based Fair Value

This value is determined by dividing the dividend per share by the average dividend yield of the selected past years for smoothing. A higher fair value than the market price indicates an undervalued stock.

Example 2022

Fair Value Dividend 2022 = Dividend per Share 2022 * Average Dividend Yield 2019 - 2021 (3 Years Smoothing)

Expectations and Forecasts

Future expectations provide potential trajectories for stock prices and aid investors in decision-making. The expected values are forecasted figures of fair value, taking into account the growth or decline trends of profit, revenue, or dividend.

Comparative Analysis

Comparing the fair value based on profit, revenue, and dividend provides a holistic overview of the stock’s financial health. Observing the annual and per-annual variations contributes to understanding the consistency and reliability of stock performance.

Haisco Pharmaceutical Group Co historical P/E ratio, EBIT multiple, and P/S ratio

LIMITED TIME OFFER

The World’s Best Investors Are On Eulerpool

Subscribe for $2

Haisco Pharmaceutical Group Co shares outstanding

The number of shares was Haisco Pharmaceutical Group Co in 2023 — This indicates how many shares 1.093 B is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Number of stocks
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Haisco Pharmaceutical Group Co earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Haisco Pharmaceutical Group Co's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Haisco Pharmaceutical Group Co’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Haisco Pharmaceutical Group Co's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Haisco Pharmaceutical Group Co stock splits

In Haisco Pharmaceutical Group Co's history, there have been no stock splits.

Haisco Pharmaceutical Group Co dividend history and estimates

In 2023, Haisco Pharmaceutical Group Co paid a dividend amounting to 0 CNY. Dividend means that Haisco Pharmaceutical Group Co distributes a portion of its profits to its owners.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Dividend
Dividend (Estimate)
Details

Dividend

ⓘ

Dividend Overview

The dividend per year chart for Haisco Pharmaceutical Group Co provides a comprehensive view of the annual dividends distributed to shareholders. Analyze the trend to understand the consistency and growth in dividend payouts over the years.

Interpretation and Use

A consistent or increasing trend in dividends can indicate the company's profitability and financial health. Investors can use this data to identify Haisco Pharmaceutical Group Co’s potential for long-term investment and income generation through dividends.

Investment Strategy

Incorporate the dividend data in evaluating Haisco Pharmaceutical Group Co's overall performance. A thorough analysis, considering other financial aspects, will help in making informed investment decisions for optimal capital growth and income generation.

Haisco Pharmaceutical Group Co Dividend History

DateHaisco Pharmaceutical Group Co Dividend
2026e0.57 CNY
2025e0.42 CNY
2024e0.33 CNY
20220.19 CNY
20210.37 CNY
20200.09 CNY
20190.19 CNY
20180.28 CNY
20170.46 CNY
20160.25 CNY
20150.2 CNY
20140.25 CNY
20130.28 CNY
20120.22 CNY

Haisco Pharmaceutical Group Co dividend payout ratio

In 2023, Haisco Pharmaceutical Group Co had a payout ratio of 67.63%. The payout ratio indicates the percentage of the company's profits that Haisco Pharmaceutical Group Co distributes as dividends.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Payout ratio
Details

Payout ratio

ⓘ

What is Yearly Payout Ratio?

The yearly payout ratio for Haisco Pharmaceutical Group Co represents the proportion of earnings paid out as dividends to shareholders. It is an indicator of the company's financial health and stability, illustrating how much profit is being returned to investors versus being reinvested back into the company.

How to Interpret the Data

A lower payout ratio for Haisco Pharmaceutical Group Co could mean that the company is reinvesting more into its growth, whereas a higher ratio indicates more earnings are being distributed as dividends. Investors seeking regular income might prefer companies with a higher payout ratio, while those looking for growth may opt for companies with a lower ratio.

Using the Data for Investments

Evaluate Haisco Pharmaceutical Group Co's payout ratio in conjunction with other financial metrics and performance indicators. A sustainable payout ratio, coupled with strong financial health, can indicate a reliable dividend payout. However, a very high ratio might suggest the company is not sufficiently reinvesting in its future growth.

Haisco Pharmaceutical Group Co Payout Ratio History

DateHaisco Pharmaceutical Group Co Payout ratio
2026e75.74 %
2025e74.61 %
2024e84.98 %
202367.63 %
202271.23 %
2021116.08 %
202015.58 %
201941.3 %
201890.32 %
2017209.09 %
201660.98 %
201557.14 %
201459.52 %
201357.88 %
201254.2 %
201167.63 %
201067.63 %
200967.63 %
200867.63 %
LIMITED TIME OFFER

The World’s Best Investors Are On Eulerpool

Subscribe for $2
Unfortunately, there are currently no price targets and forecasts available for Haisco Pharmaceutical Group Co.

Haisco Pharmaceutical Group Co latest earnings and earnings surprises

DateEPS EstimateEPS ActualQuarterly report
12/31/20190.1 CNY0.2 CNY (98.02 %)2019 Q4
9/30/20190.12 CNY0.14 CNY (15.51 %)2019 Q3
6/30/20190.16 CNY0.17 CNY (4.94 %)2019 Q2
12/31/20180.01 CNY0.03 CNY (197.03 %)2018 Q4
12/31/20160.12 CNY0.13 CNY (7.26 %)2016 Q4
9/30/20160.09 CNY0.07 CNY (-22.99 %)2016 Q3
12/31/20140.23 CNY0.09 CNY (-61.26 %)2014 Q4
9/30/20140.26 CNY0.12 CNY (-54.3 %)2014 Q3
6/30/20140.24 CNY0.13 CNY (-46.37 %)2014 Q2
12/31/20130.37 CNY0.15 CNY (-59.86 %)2013 Q4
1
2

Eulerpool ESG Scorecard© for the Haisco Pharmaceutical Group Co stock

Eulerpool World ESG Rating (EESG©)

47/ 100

🌱 Environment

37

👫 Social

42

🏛️ Governance

63

Environment

Scope 1 - Direct Emissions
Scope 2 - Indirect emissions from purchased energy
Scope 3 - Indirect emissions within the value chain
Total CO₂ emissions
CO₂ reduction strategy
Coal energy
Nuclear power
Animal experiments
Fur & Leather
Pesticides
Palm Oil
Tobacco
Genetically modified organisms
Climate concept
Sustainable forestry
Recycling regulations
Environmentally friendly packaging
Hazardous substances
Fuel consumption and efficiency
Water consumption and efficiency

Social

Percentage of female employees
Percentage of women in management
Percentage of Asian employees
Share of Asian management
Percentage of Hispanic/Latino employees
Hispano/Latino Management share
Percentage of Black employees
Black Management Share
Percentage of white employees
White Management Share
Adult content
Alcohol
Weapons
Firearms
Gambling
Military contracts
Human rights concept
Privacy concept
Occupational health and safety
Catholic

Governance (Corporate Governance)

Environmental reporting
Stakeholder Engagement
Call Back Policies
Antitrust law

The Eulerpool ESG Scorecard© is the strictly copyrighted intellectual property of Eulerpool Research Systems. Any unauthorized use, imitation, or infringement will be actively pursued and may lead to significant legal consequences. For licenses, collaborations, or usage rights, please contact us directly via our contact form. Contact Form to us.

Haisco Pharmaceutical Group Co shareholders

%
Name
Stocks
Change
Date
35.67669 % Wang (Jun Min)399,550,40006/30/2024
19.40456 % Fan (Xiu Lian)217,315,60006/30/2024
13.76244 % Zheng (Wei)154,128,30006/30/2024
4.97410 % Shen (Ping)55,705,89406/30/2024
3.78976 % Yang (Fei)42,442,28606/30/2024
1.43308 % Fullgoal Fund Management Co., Ltd.16,049,3208,632,1206/30/2024
1.40513 % China Universal Asset Management Co., Ltd.15,736,3451,854,5416/30/2024
0.90415 % China Southern Asset Management Co. Ltd.10,125,7267,620,6516/30/2024
0.77968 % Zhong Ou Asset Management Co., Ltd.8,731,8172,137,3916/30/2024
0.68849 % China Life Asset Management Company Limited7,710,590-3,079,6536/30/2024
1
2
3
4
5
...
10

Haisco Pharmaceutical Group Co Executives and Management Board

Mr. Pangke Yan

(42)
Haisco Pharmaceutical Group Co Deputy General Manager, Director (since 2021)
Compensation 6.22 M CNY

Mr. Junmin Wang

(54)
Haisco Pharmaceutical Group Co Chairman of the Board (since 2007)
Compensation 1.73 M CNY

Mr. Peng Duan

(47)
Haisco Pharmaceutical Group Co Chief Financial Officer
Compensation 1.49 M CNY

Mr. Meng Wang

(37)
Haisco Pharmaceutical Group Co Deputy General Manager, Secretary of the Board
Compensation 1.28 M CNY

Ms. Xiulian Fan

(59)
Haisco Pharmaceutical Group Co General Manager, Director (since 2007)
Compensation 882,800 CNY
1
2
3

Haisco Pharmaceutical Group Co Supply Chain

NameRelationshipTwo-week correlationOne-month correlationThree-Month CorrelationSix-Month CorrelationOne Year CorrelationTwo-Year Correlation
Aquestive Therapeutics Stock
Aquestive Therapeutics
SupplierCustomer0,720,760,740,680,340,43
1

Most common questions regarding Haisco Pharmaceutical Group Co

What is the P/E ratio of Haisco Pharmaceutical Group Co 2024?

The Haisco Pharmaceutical Group Co P/E ratio is 85.44.

What is the P/S ratio of Haisco Pharmaceutical Group Co 2024?

The Haisco Pharmaceutical Group Co P/S ratio is 9.06.

What is the Quality Investing of Haisco Pharmaceutical Group Co?

The Quality Investing for Haisco Pharmaceutical Group Co is 4/10.

What is the revenue of Haisco Pharmaceutical Group Co 2024?

The expected Haisco Pharmaceutical Group Co revenue is 4.08 B CNY.

How high is the profit of Haisco Pharmaceutical Group Co 2024?

The expected Haisco Pharmaceutical Group Co profit is 432.65 M CNY.

What is the business model of Haisco Pharmaceutical Group Co

No history available for Haisco Pharmaceutical Group Co.

What is the Haisco Pharmaceutical Group Co dividend?

Haisco Pharmaceutical Group Co pays a dividend of 0.19 CNY distributed over payouts per year.

How often does Haisco Pharmaceutical Group Co pay dividends?

The dividend cannot currently be calculated for Haisco Pharmaceutical Group Co or the company does not pay out a dividend.

What is the Haisco Pharmaceutical Group Co ISIN?

The ISIN of Haisco Pharmaceutical Group Co is CNE100001BC7.

What is the Haisco Pharmaceutical Group Co ticker?

The ticker of Haisco Pharmaceutical Group Co is 002653.SZ.

How much dividend does Haisco Pharmaceutical Group Co pay?

Over the past 12 months, Haisco Pharmaceutical Group Co paid a dividend of 0.19 CNY . This corresponds to a dividend yield of about 0.55 %. For the coming 12 months, Haisco Pharmaceutical Group Co is expected to pay a dividend of 0.42 CNY.

What is the dividend yield of Haisco Pharmaceutical Group Co?

The current dividend yield of Haisco Pharmaceutical Group Co is 0.55 %.

When does Haisco Pharmaceutical Group Co pay dividends?

Haisco Pharmaceutical Group Co pays a quarterly dividend. This is distributed in the months of May, August, June, October.

How secure is the dividend of Haisco Pharmaceutical Group Co?

Haisco Pharmaceutical Group Co paid dividends every year for the past 3 years.

What is the dividend of Haisco Pharmaceutical Group Co?

For the upcoming 12 months, dividends amounting to 0.42 CNY are expected. This corresponds to a dividend yield of 1.24 %.

In which sector is Haisco Pharmaceutical Group Co located?

Haisco Pharmaceutical Group Co is assigned to the 'Health' sector.

Wann musste ich die Aktien von Haisco Pharmaceutical Group Co kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Haisco Pharmaceutical Group Co from 9/18/2024 amounting to 0.145 CNY, you needed to have the stock in your portfolio before the ex-date on 9/18/2024.

When did Haisco Pharmaceutical Group Co pay the last dividend?

The last dividend was paid out on 9/18/2024.

What was the dividend of Haisco Pharmaceutical Group Co in the year 2023?

In the year 2023, Haisco Pharmaceutical Group Co distributed 0.185 CNY as dividends.

In which currency does Haisco Pharmaceutical Group Co pay out the dividend?

The dividends of Haisco Pharmaceutical Group Co are distributed in CNY.

All fundamentals about Haisco Pharmaceutical Group Co

Our stock analysis for Haisco Pharmaceutical Group Co Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Haisco Pharmaceutical Group Co Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.